Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.16 -0.63%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
INLB, FTXP, EDXC, More
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
INLB, FTXP, EDXC, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.25), $0.19 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $190.7 million versus the consensus estimate of $206.03 million.
GUIDANCE:
Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Kaiser Aluminum Corporation (KALU) to Buy
- Macquarie Double Upgrades BYD Electronic International Co Ltd. (285:HK) (BYDIF) to Outperform
- Jefferies Upgrades Zhejiang Dingli Machinery (603338:CH) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
